Skip to main content

Table 1 Baseline characteristics of study participants by treatment group. Data are given as mean (SD), median [IQR] or frequencies

From: Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial

 

Calcitriol

Placebo

P

N

20

20

 

Age (years)

58.7 ± 9.4

62.4 ± 10.1

0.25

Male sex, N (%)

10 (50)

12 (60)

0.53

Black race, N (%)

12 (60)

15 (75)

0.31

BMI (kg/m2)

30.0 ± 6.2

33.4 ± 8.8

0.16

SBP (mmHg)

135.3 ± 26.6

130.1 ± 22.0

0.50

DBP (mmHg)

75.9 ± 12.3

71.8 ± 11.6

0.28

Laboratory variables

 Calcium (mg/dL)

9.1 ± 0.5

9.3 ± 0.3

0.14

 Phosphorus (mg/dL)

3.87 ± 0.58

3.94 ± 0.65

0.22

 PTH (pg/ml)

100.7 ± 73.6

108.4 ± 60.3

0.38

 Hemoglobin (g/dL)

12.2 ± 1.9

13.3 ± 1.7

0.06

 eGFR (mg/min)

35.8 ± 11.7

40.6 ± 10.8

0.19

 UACR (mg/g)

254 [8, 2540]

39 [13, 188]

0.29

 Hepcidin (ng/ml)

71.7 [46.5, 195.6]

76.1 [46.3, 124.1]

0.81

 TSAT (%)

25.3 ± 12.5

23.2 ± 8.1

0.53

 Ferritin (mg/dL)

193.5 [92.5, 374.5]

174.5 [66.0, 319.0]

0.34

  1. Abbreviations: BMI Body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, UACR urine albumin to creatinine ratio, TSAT transferrin saturation